Every Form 4 that BioAge Labs, Inc. (BIOA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BIOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIOA filings page.
BioAge Labs, Inc. principal accounting officer Shane Barton exercised stock options and sold shares of common stock in late June. He exercised options covering 59,934 shares at strike prices between $4.30 and $10.85 per share, then sold a total of 62,566 shares in open-market transactions at weighted average prices around $25 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and after these trades he reported holding no shares of common stock directly.
BioAge Labs, Inc. director Vijay Satyanand Pande received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and expire on June 9, 2036, bringing his directly held option position reported here to 22,000 shares. The entire award vests on the earlier of the next annual stockholder meeting or one year from the grant date, if he continues serving the company.
BioAge Labs, Inc. director Rekha Hemrajani received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or one year from the grant date, subject to her continued service. Following this grant, she holds options for 22,000 shares directly.
BioAge Labs, Inc. director James Healy received a grant of stock options tied to the company’s common stock. The award covers 22,000 options with an exercise price of $15.48 per share and expires on June 9, 2036.
According to the terms, the entire option award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided Healy continues to serve the company through the applicable vesting date. After this grant, he holds 22,000 derivative securities directly.
BioAge Labs, Inc. director Patrick G. Enright received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and were awarded as compensation rather than purchased in the open market.
These options vest in full on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Enright continues to serve the company through that vesting date. Following this grant, he holds 22,000 stock options directly.
BioAge Labs, Inc. director Michael H. Davidson received a grant of stock options covering 22,000 shares of common stock. These options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. Following this grant, Davidson holds 22,000 stock options directly.
BioAge Labs, Inc. director Jean Pierre Garnier received a grant of stock options covering 22,000 shares of common stock at an exercise price of $15.48 per share. The options vest in full on the earlier of the next annual stockholder meeting or one year from the grant date, subject to continued service, and expire on June 9, 2036.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein exercised stock options for 3,542 shares of common stock at $4.38 per share. Following the exercise, he directly holds 36,575 common shares and 155,833 stock options, which vest in equal monthly installments through their February 17, 2035 expiration.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and then sold the resulting shares. On April 1, 2026, he exercised options covering 8,820 shares of common stock at strike prices of $4.11 and $6.57 per share.
The same day, he sold 8,820 shares of common stock at $17.81 per share in an open-market transaction, leaving 0 shares of common stock held directly after the sale. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and sold the resulting shares. On March 2, 2026, he exercised options for a total of 7,433 shares of common stock at exercise prices of $4.11 and $6.57 per share. He then sold all 7,433 common shares in an open-market transaction at $20.30 per share, leaving him with zero directly held common shares after the sale. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and the options exercised were fully vested, with vesting beginning on April 1, 2022 and the award becoming fully vested on May 11, 2024.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein reported exercising stock options and receiving common shares. On March 1, 2026, he exercised options for 3,542 shares of common stock at $4.38 per share through an option conversion.
After these transactions, he held 33,033 shares of common stock directly and 159,375 stock options directly. The option award vests in equal monthly installments over 48 months, with vesting that began on February 1, 2025, subject to his continued service.
BioAge Labs, Inc. reported that Chief Medical Officer Paul D. Rubin acquired a stock option award covering 110,000 shares of common stock. The option was granted at an exercise price of $0.00 per share and is held as a direct ownership position.
According to the vesting terms, the option vests in equal monthly installments of 1/48th of the total award. The first tranche vested on February 1, 2026, with each remaining monthly tranche scheduled to vest on the monthly anniversary of that date, as long as Rubin continues to provide service to the company on each vesting date.
Morgen Eric reported acquisition or exercise transactions in this Form 4 filing.
BioAge Labs, Inc. director and Chief Operating Officer Morgen Eric reported receiving new stock option awards. One option grant covers 110,000 shares held directly, and a separate option grant covers 12,500 shares held indirectly by the reporting person's spouse.
Each option vests in equal monthly installments of 1/48 of the total award, with the first tranche vested on February 1, 2026 and additional tranches vesting on each monthly anniversary. Vesting depends on continued service to BioAge Labs on each vesting date.
GOLDSTEIN DOV A MD reported acquisition or exercise transactions in this Form 4 filing.
BioAge Labs, Inc. reported that its Chief Financial Officer, Dov A. Goldstein, received a grant of stock options covering 110,000 shares of the company’s stock. The options were granted at no cash cost to the executive on the grant date.
According to the vesting terms, the award vests in 48 equal monthly installments. The first 1/48th portion vested on February 1, 2026, with each remaining monthly tranche vesting on the same monthly anniversary, so long as the CFO continues to provide service to BioAge on each vesting date.
Fortney Kristen reported acquisition or exercise transactions in this Form 4 filing.
BioAge Labs, Inc. director and Chief Executive Officer Kristen Fortney reported receiving a grant of stock options on February 17, 2026. The award covers 330,000 options with direct ownership. The options vest in equal monthly installments over four years, starting February 1, 2026, as long as she continues serving the company.
BioAge Labs, Inc. reported that Principal Accounting Officer Barton Shane received a grant of stock options covering 45,000 shares of common stock. The options were awarded at an exercise price of $0.0000 per share, reflecting a compensatory equity award rather than an open-market purchase.
According to the terms, the option vests in equal 1/48th monthly installments, with the first tranche vesting on February 1, 2026. Each subsequent tranche will vest on the monthly anniversary of that date, conditioned on Shane’s continued service with BioAge Labs on each vesting date.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported option exercises and a share sale in the company’s stock. On February 2, 2026, he exercised stock options for 5,433 shares at $4.11 and 2,000 shares at $6.57 of common stock.
On the same date, he sold 7,433 shares of common stock at $18.75 per share, leaving him with 0 shares of common stock held directly after the reported transactions. The filing notes that the sale was executed under a Rule 10b5-1 trading plan adopted on November 5, 2024. He continues to hold stock options, including awards that are fully vested or vest monthly over time.
BioAge Labs, Inc. Chief Financial Officer exercises stock options and acquires shares. On February 1, 2026, CFO Dov A. Goldstein exercised options to buy 3,541 shares of BioAge Labs common stock at $4.38 per share. Following this transaction, he directly owns 29,491 common shares and holds 162,917 stock options that are still outstanding.
The options vest in equal monthly installments over four years, with 1/48th of the award vesting each month starting on February 1, 2025, conditioned on continued service to the company.
BioAge Labs, Inc. CFO Dov A. Goldstein reported an option exercise and related stock acquisition. On January 16, 2026, he exercised a stock option for 3,542 shares of common stock at an exercise price of $4.38 per share, coded as an "M" transaction.
The derivative table shows this option carried a conversion price of $4.38 and an expiration date of February 17, 2035. Following the transaction, Goldstein held 25,950 shares of BioAge common stock directly and 166,458 stock options directly. The option vests in equal monthly installments of 1/48th of the total award, starting on February 1, 2025, contingent on continued service.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein reported a same-day option exercise and share sales. On January 13, 2026, he exercised stock options for 27,000 shares of common stock at an exercise price of $8.39 per share, then sold 27,000 shares in multiple transactions at weighted-average prices of $18.4278, $19.4526, $20.5392 and $21.0808 per share. A footnote states that at least one transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2024. After these trades, he holds 22,408 shares of common stock directly, and the option award provides for monthly vesting and an early exercise feature.
BioAge Labs, Inc. Chief Executive Officer and director Kristen Fortney reported selling 233,107 shares of the company’s common stock on January 13, 2026. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2024, which is designed to allow insiders to systematically trade shares over time.
The shares were sold at a weighted average price of $18.1163 per share, with individual sale prices ranging from $18.00 to $18.385 per share. After this transaction, Fortney beneficially owns 976,949 shares of BioAge Labs common stock in direct ownership.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported option exercises and a share sale. On January 2, 2026, he exercised stock options to acquire 5,433 common shares at $4.11 per share and 2,000 common shares at $6.57 per share. On the same day he sold 7,433 common shares at a weighted average price of $12.8468 per share, with individual sale prices ranging from $12.571 to $13.242. Following these transactions, he directly held no shares of common stock but continued to hold stock options, including 16,303 options at $4.11 and 7,383 options at $6.57. The activity was carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024.
BioAge Labs' Chief Medical Officer reported an insider transaction involving 18,000 shares of common stock on December 9, 2025. The officer exercised stock options to buy 18,000 shares at $6.57 per share and then sold the same 18,000 shares at $12 per share, resulting in no directly held common stock after the sale.
The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2024. Following the exercise, the officer continues to hold 9,383 stock options with a $6.57 exercise price, which vest in 1/48th monthly installments that began on April 1, 2022, and have an expiration date of May 28, 2032.